Navigation Links
New Technologies Open the Door for Low Dose Breast-Specific Gamma Imaging (BSGI) / Molecular Breast Imaging (MBI)
Date:3/17/2011

LAS VEGAS, March 17, 2011 /PRNewswire/ -- A new study by Craig Thiessen, M.D., Director of Radiology for West Houston Radiology L.L.P. and North Cypress Medical Center in Houston, presented this week at the National Consortium of Breast Centers Annual Meeting, found the improved photon sensitivity of new detector technologies such as PSPMTs and CZT should be capable of reducing the radiation dose patient receive from BSGI/MBI studies by 75%.  However, low dose imaging is currently an off-label use of the radiopharmaceutical, and there are several prospective patient studies underway to validate the clinical feasibility of low dose imaging.

BSGI/MBI is a molecular imaging tool for detecting early stage breast cancer, particularly for women who are at increased risk for the disease or have dense breast tissue.  BSGI/MBI utilizes a radiopharmaceutical to visualize metabolic activity, revealing highly active areas that may be indicative of disease.  A primary benefit of BSGI/MBI is that the exam provides a physiological map complementary to the anatomical map produced by mammography, and its ability to detect cancer is not affected by dense breast tissue as mammograms often are.  It is also especially useful when mammographic or ultrasonic imaging studies are normal or discordant in the presence of clinical signs and symptoms.

Dr. Thiessen, a nuclear medicine specialist and breast imager, said that "BSGI/MBI- as with PET imaging, shows that molecular imaging is more advantageous in conjunction with standard anatomical evaluation of the body, and specifically the breast.  Mammography, ultrasound and MRI look at various structures and patterns, whereas BSGI/MBI looks at the breast on a cellular level to help determine the presence or absence of disease."

Dr. Thiessen notes that MBI with the Dilon 6800 Gamma Camera is as sensitive, more specific and more cost-effective than performing a diagnostic work-up with MRI.  "BSGI/MBI is as safe and efficacious as other primary radiological exams; and even as new studies demonstrate that we can use lower doses to evaluate the breast, the current recommended dose is safe and only slightly higher than mammography," said Thiessen.

Dilon Diagnostics currently has the only FDA approved localization system for gamma-guided biopsy.  Thiessen concludes that "To date, Dilon's localization system/GammaLoc® has shown sensitivity for diagnosis of areas of concern, and will advance breast imaging to a new level; where I believe that molecular imaging reveals changes that happen on a cellular level before we can see differences in structural recognition."

About Dilon Diagnostics

Dilon Diagnostics, a brand of Dilon Technologies Inc., is bringing innovative medical imaging products to market.  Dilon's cornerstone product, the Dilon 6800, is a digital high-resolution, compact gamma camera optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake.  Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston.  For more information on Dilon Diagnostics please visit www.dilon.com.


'/>"/>
SOURCE Dilon Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Netsmart Technologies Named NACo Premier Partner of the Year
2. China Medical Technologies to Meet Investors
3. Electricity Sparks Interest in New Technologies and Cosmeceuticals for Aging Skin
4. Los Angeles Dentist, Dr. Kevin Sands, Uses the Latest Technologies to Provide VIP Services and Treatments for His Patients
5. FDA Grants 510(k) Clearance to Life Technologies Stem Cell Growth Medium
6. BioSpecifics Technologies Corp. to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference
7. Reportlinker Adds Gene Therapy - Technologies, Markets and Companies
8. Reportlinker Adds Proteomics - Technologies, Markets and Companies
9. RainDance Technologies and Ambry Genetics Expand Collaboration to Address ADME Analysis
10. FDA Clears Palatin Technologies IND Filing to Commence Clinical Studies for Asthma
11. Palatin Technologies, Inc. Closes $23 Million Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , Sept. ... Penn. , and OptiMed Specialty Pharmacy of ... partnership to offer a strategic hub service that expedites ... highly sought-after personal spirometer, Spiro PD 2.0, and wellness ... A spirometer is a medical device used to measure ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
Breaking Medicine News(10 mins):